Skip to main content

Advertisement

SpringerLink
Log in

Empfehlungen zum Einsatz von Rituximab bei Patienten mit rheumatoider Arthritis

Recommendations for use of rituximab in patients with rheumatoid arthritis

  • Empfehlungen und Stellungnahmen von Fachgesellschaften
  • Published:
Zeitschrift für Rheumatologie Aims and scope Submit manuscript

Zusammenfassung

Seit 2006 ist Rituximab (RTX) für die Behandlung von Patienten mit rheumatoider Arthritis zugelassen, die auf eine frühere TNF-Blockertherapie nicht angesprochen bzw. diese nicht vertragen haben. In diesen überarbeiteten Therapieempfehlungen werden neue Studiendaten zur Evaluation des therapeutischen Ansprechens, zur Retherapie sowie die Bedeutung von prädiktiven Faktoren für das Ansprechen und Sicherheitsaspekte aktualisiert und diskutiert.

Abstract

Treatment with rituximab (RTX) has been approved since 2006 for patients with rheumatoid arthritis who previously failed to respond to tumor necrosis factor (TNF) inhibitor therapy or who experienced side effects. In these updated treatment recommendations new data relating to evaluation of the therapeutic response, retreatment, the role of predictive factors as well as safety data are incorporated and discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Smolen J, Keystone EC, Emery P et al (2007) Consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 66:143–150

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  2. Buch MH, Smolen JS, Betteridge N et al (2011) Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 70:909–920

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  3. Schneider M, Lelgemann M, Abholz HH et al (2011) Interdisziplinäre Leitline: Management der frühen rheumatoiden Arthritis. 3. überarb. Aufl. Springer, Heidelberg Berlin New York

  4. Smolen JS, Aletaha D, Bijlsma JW et al (2010) Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 69:631–637

    Article  PubMed Central  PubMed  Google Scholar 

  5. Cohen SB, Emery P, Greenwald MW et al (2006) Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 54:2793–2806

    Article  PubMed  CAS  Google Scholar 

  6. Cohen SB, Keystone E, Genovese MC et al (2010) Continued inhibition of structural damage over 2 years in patients with rheumatoid arthritis treated with rituximab in combination with methotrexate. Ann Rheum Dis 69:1158–1161

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  7. Krüger K, Wollenhaupt J, Albrecht K et al (2012) S1-Leitlinie der DGRh zur sequenziellen medikamentösen Therapie der rheumatoiden Arthritis. Z Rheumatol 71:592–603

    Article  PubMed  CAS  Google Scholar 

  8. Gottenberg J, Ravaud P, Bardin T et al (2009) Prospective follow-up of rituximab treatment in 1407 patients with refractory rheumatoid arthritis (1175 patients/year): tolerance and efficacy data from the French AIR (Autoimmunity and Rituximab) registry. Ann Rheum Dis 68(Suppl 3):442

    Article  Google Scholar 

  9. Wendler J, Tony H, Krause A et al (2008) The German rituximab treatment of active rheumatoid arthritis in daily practise trial: second interim analysis of effectiveness and safety after 15 months. Ann Rheum Dis 67(Suppl II):340

    Google Scholar 

  10. Emery P, Deodhar A, Rigby WF et al (2010) Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab’s Efficacy in MTX iNadequate rEsponders (SERENE)). Ann Rheum Dis 69:1629–1635

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  11. Rubbert-Roth A, Tak PP, Zerbini C et al (2010) Efficacy and safety of various repeat treatment dsoing regimens of rituximab in patients with active rheumatoid arthritis: results of a phase III randomized study (MIRROR). Rheumatology (Oxford) 49:1683–1693

    Google Scholar 

  12. Tak PP, Rigby WE, Rubbert-Roth A et al (2011) Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial. Ann Rheum Dis 70:39–46

    Article  PubMed  CAS  Google Scholar 

  13. Tak PP, Rigby WE, Rubbert-Roth A et al (2012) Sustained inhibition of progressive joint damage with rituximab and methotrexate in early active rheumatoid arthritis: 2-year results from the randomised controlled trial IMAGE. Ann Rheum Dis 71:351–357

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  14. Emery P, Keystone E, Tony HP et al (2008) IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 67:1516–1523

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  15. Genovese MC, Becker JC, Schiff M et al (2005) Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 353:1114–1123

    Article  PubMed  CAS  Google Scholar 

  16. Nam JL, Winthrop KL, Vollenhoven RF van et al (2010) Current evidence fort he management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations fort he management of RA. Ann Rheum Dis 69:976–986

    Article  PubMed  CAS  Google Scholar 

  17. Finckh A, Möller B, Dudler J et al (2010) Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent? Ann Rheum Dis 69:387–393

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  18. Chatzidionysiou K, Lie E, Nasonov E et al (2011) Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries. Ann Rheum Dis 70:1575–1580

    Article  PubMed  CAS  Google Scholar 

  19. Hauser SL, Waubant E, Arnold DL et al (2008) B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 358:676–688

    Article  PubMed  CAS  Google Scholar 

  20. Keystone E, Emery P, Peterfy CG et al (2009) Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies. Ann Rheum Dis 68:216–221

    Article  PubMed  CAS  Google Scholar 

  21. Silverman GJ, Schwartzman S, Townsend M et al (2009) Identification of biomarkers for enhanced benefit to rituximab in rheumatoid arthritis: role of autoantibodies and inflammatory markers. Arthritis Rheum 60:S1680

    Google Scholar 

  22. Strangfeld A, Eveslage M, Kekow J et al (2009) Effectiveness of treatment with rituximab depends on autoantibody status – results from 2 years of experience in the German biologics register RABBIT. Arthritis Rheum 60:S1695

    Google Scholar 

  23. Sellam J, Hendel-Chavez H, Rouanet S et al (2011) B cell activation biomarkers as predictive factors for the response to rituximab in rheumatoid arthritis. Arthritis Rheum 63:933–938

    Article  PubMed  CAS  Google Scholar 

  24. Edwards JC, Szczepanski L, Szechinski J et al (2004) Efficacy of B cell targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 350:2572–2581

    Article  PubMed  CAS  Google Scholar 

  25. Owczarzcyk K, Hellmann M, Fliedner G et al (2008) Clinical outcome and B cell depletion in patients with rheumatoid arthritis receiving rituximab monotherapy in comparison with patients receiving concomitant methotrexate. Ann Rheum Dis 67:1648–1649

    Article  CAS  Google Scholar 

  26. Keystone E, Fleischmann R, Emery P et al (2007) Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. Arthritis Rheum 56:3896–3908

    Article  PubMed  CAS  Google Scholar 

  27. Loveless JE, Olech E, Pritchard C et al (2009) An open-label, prospective study (SUNDIAL) of the safety of rituximab in combination with disease-modifying anti-rheumatic drugs in patients with active rheumatoid arthritis. Arthritis Rheum 60:S1660

    Google Scholar 

  28. Wendler J, Sorensen H, Tony H et al (2009) Effectiveness and safety of rituximab (RTX) monotherapy compared to RTX combination therapy with methotrexate or leflunomide in the German RTX treatment of active rheumatoid arthritis in daily practise trial. Ann Rheum Dis 68(Suppl 3):76

    Google Scholar 

  29. Chatzidionysiou K, Lie E, Nasonov E et al (2012) Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and leflunomide in rituximab-treated rheumatoid arthritis patients: results of a 1-year follow-up study from the CERERRA collaboration. Ann Rheum Dis 71:374–377

    Article  PubMed  CAS  Google Scholar 

  30. Rigby W, Mease P, Olech E et al (2011) An open-label study of the safety of rituximab (RTX) in combination with other biologic disease-modifying antirheumatic drugs (DMARDs) in patients with active rheumatoid arthritis. Ann Rheum Dis 70(Suppl 3):623

    Google Scholar 

  31. Greenwald MW, Shergy WJ, Kaine JL et al (2011) Evaluation of the safety of rituximab in combination with a tumor necrosis factor inhibitor and methotrexate in patients with active rheumatoid arthritis. Arthritis Rheum 63:622–632

    Article  PubMed  CAS  Google Scholar 

  32. Kimby E (2005) Tolerability and safety of rituximab (MabThera). Cancer Treat Rev 31:456–473

    Article  PubMed  CAS  Google Scholar 

  33. Pei SN, Chen CH, Lee CM et al (2010) Reactivation of hepatitis B virus following rituximab-based regimens: a serious complication in both HBsAg-positive and HBsAg negative patients. Ann Hematol 89:255–262

    Article  PubMed  CAS  Google Scholar 

  34. Koo YX, Tan DS, Tan BH et al (2009) Risk of hepatitis B virus reactivation in patients who are hepatitis B surface antigen negative/antibody to hepatitis B core antigen positive and the role of routine antiviral prophylaxis. J Clin Oncol 27:2570–2571 (Antwort des Autors 2571–2572)

    Article  PubMed  Google Scholar 

  35. Pyrpasopoulou A, Douma S, Vassiliadis T et al (2011) Reactivation of chronic hepatitis B virus infection following rituximab administration for rheumatoid arthritis. Rheumatol Int 31:403–404

    Article  PubMed  Google Scholar 

  36. Ziakas PD, Karsaliakos P, Mylonakis E (2009) Effect of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in lymphoma: a meta-analysis of published clinical trials and a decision tree addressing prolonged prophylaxis and maintenance. Haematologica 94:998–1005

    Article  PubMed Central  PubMed  Google Scholar 

  37. Dizdar O, Tapan U, Aksoy S et al (2008) Liver dysfunction after chemotherapy in lymphoma patients infected with hepatitis C. Eur J Haematol 80:381–385

    Article  PubMed  CAS  Google Scholar 

  38. De Vita S, Quartuccio L, Isola M et al (2012) A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis. Arthritis Rheum 64:843–853

    Article  CAS  Google Scholar 

  39. Van Vollenhoven RF, Emery P, Bingham CO et al (2010) Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials. J Rheumatol 37:558–567

    Article  CAS  Google Scholar 

  40. Gottenberg JE, Ravaud P, Bardin T et al (2010) Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and ritxuimab registry. Arthritis Rheum 62:2625–2632

    Article  PubMed  CAS  Google Scholar 

  41. Roll P, Palanichamy A, Kneitz C et al (2006) Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis. Arthritis Rheum 54:2377–2386

    Article  PubMed  CAS  Google Scholar 

  42. Leandro MJ, Cambridge G, Ehrenstein MR et al (2006) Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum 54:613–620

    Article  PubMed  CAS  Google Scholar 

  43. Bingham CO III, Looney RJ, Deodhar A et al (2010) Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial. Arthritis Rheum 62:64–74

    Article  PubMed  CAS  Google Scholar 

  44. Van Assen S, Holvast A, Benne CA et al (2010) Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab. Arthritis Rheum 62:75–81

    Article  CAS  Google Scholar 

  45. Van Assen S, Agmon-Levin N, Elkayam O et al (2011) EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 70:414–422

    Article  CAS  Google Scholar 

  46. Mei HE, Yoshida T, Sime W et al (2009) Blood-borne human plasma cells in steady state are derived from mucosal immune responses. Blood 113:2461–2469

    Article  PubMed  CAS  Google Scholar 

  47. Dass S, Rawstron AC, Vital EM et al (2008) Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis. Arthritis Rheum 58:2993–2999

    Article  PubMed  CAS  Google Scholar 

  48. Teng YK, Levarht EW, Toes RE et al (2009) Residual inflammation after rituximab treatment is associated with sustained synovial plasma cell infiltration and enhanced B cell repopulation. Ann Rheum Dis 68:1011–1016

    Article  PubMed  CAS  Google Scholar 

  49. Emery P, Mease P, Rubbert-Roth A et al (2011) Retreatment with rituximab based on a treatment to target approach provides better disease control than treatment as needed in patients with rheumatoid arthritis: a retrospective pooled analysis. Rheumatology 50:2223–2232

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  50. Vital E, Dass S, Buch MH et al (2010) A randomised double-blind placebo controlled trial on the effects of increased dose rituximab in patients with initial incomplete depletion-the extended treatment with rituximab in rheumatoid arthritis (EXTRRA) trial. Ann Rheum Dis 69(Suppl 3):147

    Article  Google Scholar 

  51. Owczarczyk KM, Maizus K, Roehrs T et al (2008) The clinical efficacy of repeated courses of rituximab and the kinetics of B cell depletion in primary rituximab non-responders. Ann Rheum Dis 67(Suppl II):610

    Article  CAS  Google Scholar 

  52. Thurlings RM, Vos K, Gerlag DM et al (2008) Disease-activity guided rituximab therapy in rheumatoid arthritis: the effects of re-treatment in initial non-responders versus initial responders. Arthritis Rheum 58:3657–3664

    Article  PubMed  CAS  Google Scholar 

  53. Genovese MC, Breedveld FC, Emery P et al (2009) Safety of biological therapies following rituximab treatment in rheumatoid arthritis patients. Ann Rheum Dis 68:1894–1897

    Article  PubMed  CAS  Google Scholar 

  54. Gottenberg JE, Flipo R, Cantagrel A et al (2010) Switching from rituximab to abatacept: tolerance data of 179 patients prospectively followed up in the Orencia in Rheumatoid Arthritis (ORA) registry. Ann Rheum Dis 69(Suppl 3):385

    Google Scholar 

  55. Hellmann M, Jung N, Owczarczyk K et al (2008) Successful treatment of rheumatoid vasculitis-associated cutaneous ulcers using rituximab in two patients with rheumatoid arthritis. Rheumatology 47:929–930

    Article  PubMed  CAS  Google Scholar 

  56. Puechal X, Gottenberg JE, Berthelot JM et al (2012) Rituximab therapy for systemic vasculitis associated with rheumatoid arthritis: results from the autoimmunity and rituximab registry. Arthritis Care Res 64:331–339

    Article  CAS  Google Scholar 

  57. Salama A, Schneider U, Dörner T et al (2008) Beneficial response to rituximab in a patient with haemolysis and refractory Felty syndrome. Ann Rheum Dis 67:894–895

    Article  PubMed  CAS  Google Scholar 

  58. Dass S, Atzeni F, Vital E et al (2011) Safety of rituximab in patients with rheumatoid arthritis and concomitant lung disease. Ann Rheum Dis 70(Suppl 3):71

    Google Scholar 

  59. Thurlings RM, Teng O, Vos K et al (2010) Clinical response, pharmacokinetics, development of human anti-chimaeric antibodies, and synovial tissue response to rituximab treatment in patients with rheumatoid arthritis. Ann Rheum Dis 69:409–412

    Article  PubMed  CAS  Google Scholar 

  60. Van Vollenhoven RF, Emery P, Bingham CO et al (2012) Longterm safety of rituximab: 10-year follow-up in the rheumatoid arthritis global clinical trial programme. Ann Rheum Dis 71(Suppl 3):195

    Google Scholar 

  61. Emery P. Fleischmann RM, Filipowicz-Sosnowska A et al (2006) The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 54:1390–1400

    Article  PubMed  CAS  Google Scholar 

  62. Salmon JH, Cacoub PP, Combe BG et al (2012) Neutropenia after rituximab in rheumatoid arthritis and other autoimmune diseases is a rare events: date from the autoimmunity and rituximab registry. Arthritis Rheum 64(Suppl 10):S727

    Google Scholar 

  63. Winthrop KL, Yamashita S, Beekmann SE et al (2008) Mycobacterial and other serious infections in patients receiving anti-tumor necrosis factor and other newly approved biologic therapies: case finding through the emerging Infections Network. Clin Infect Dis 46:1738–1740

    Article  PubMed  Google Scholar 

  64. Jung N, Owczarczyk K, Hellmann M et al (2008) Efficacy and safety of rituximab in a patient with active rheumatoid arthritis and chronic disseminated pulmonary aspergillosis and history of tuberculosis. Rheumatology 47:932–933

    Article  PubMed  CAS  Google Scholar 

  65. Fleischmann RM (2009) Progressive multifocal leukoencephalopathy following rituximab treatment in a patient with rheumatoid arthritis. Arthritis Rheum 60:3225–3228

    Article  PubMed  CAS  Google Scholar 

  66. Kumar D, Bouldin TW, Berger RG (2010) A case of progressive multifocal leukoencephalopathy in a patient treated with infliximab. Arthritis Rheum 62:3191–3195

    Article  PubMed  Google Scholar 

  67. Keene DL, Legare C, Taylor E et al (2011) Monoclonal antibodies and progressive multifocal leukoencephalopathy. Can J Neurol Sci 38:565–571

    PubMed  Google Scholar 

  68. Verheyen J, Feist E, Maizus K et al (2011) Frequency of JCPyV infections in patients with rheumatoid arthritis after treatment with rituximab. Ann Rheum Dis 70(Suppl 3):608

    Google Scholar 

  69. Chakravarty EF, Murray ER, Kelman A et al (2011) Pregnancy outcome after maternal exposure to rituximab. Blood 117:1499–1506

    Article  PubMed  CAS  Google Scholar 

Download references

Einhaltung ethischer Richtlinien

Interessenkonflikt. Die Autoren weisen auf folgende Beziehungen hin: A. Rubbert-Roth: Vorträge bzw. Advisory Boards von folgenden Firmen: Abbott, Amgen, BMS, Chugai, MSD, Pfizer, Roche, UCB. G. R. Burmester: Klinische Studien für AbbVie, BMS, MedImmune, Novartis, Pfizer, Roche, UCB sowie Consulting/Lectures bei AbbVie, BMS, MSD, Novartis, Pfizer, Roche, UCB. A. Gause: Abbvie, BMS, Chugai, MSD, Roche, UCB nur Referententätigkeit und Beratung. T. Dörner: Studienunterstützung von Roche/Chugai, UCB, Sanofi und Honorare für Beratung von Roche/Chugai, UCB, Sanofi. Dieser Beitrag beinhaltet keine Studien an Menschen oder Tieren.

Author information

Authors and Affiliations

  1. Klinik I für Innere Medizin, Uniklinik Köln, Kerpener Str. 62, Haus 16, 1. OG, Raum 1.008, 50937, Köln, Deutschland

    A. Rubbert-Roth

  2. Medizinische Klinik mit Schwerpunkt Rheumatologie und Klinische Immunologie, Charité – Universitätsmedizin Berlin - Campus Mitte, Berlin, Deutschland

    G.R. Burmester & T. Dörner

  3. Schwerpunktpraxis für Rheumatologie und Autoimmunerkrankungen, Hamburg, Deutschland

    A. Gause

Authors
  1. A. Rubbert-Roth
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G.R. Burmester
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. T. Dörner
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A. Gause
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

Kommission Pharmakotherapie der DGRh

Corresponding author

Correspondence to A. Rubbert-Roth.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rubbert-Roth, A., Burmester, G., Dörner, T. et al. Empfehlungen zum Einsatz von Rituximab bei Patienten mit rheumatoider Arthritis. Z. Rheumatol. 73, 165–174 (2014). https://doi.org/10.1007/s00393-013-1238-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00393-013-1238-2

Schlüsselwörter

Keywords

Search

Navigation